Monopar Therapeutics Inc. (MNPR) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Ten analysts rate Monopar Therapeutics “Moderate Buy,” with six buys, one strong buy, two holds and one sell. The average 12-month price target is $122, compared with a recent price of $78.96.
• Monopar reported a quarterly loss of $0.62 per share, narrowly beating the consensus estimate of a $0.64 loss. Analysts expect a full-year loss of approximately $2.98 per share.
• Insiders have recently reduced their holdings: Executives and directors sold 44,688 shares worth about $4.0 million over the past 90 days, though the transactions were made under pre-arranged Rule 10b5-1 plans. Monopar is a clinical-stage biotechnology company developing cancer treatments and diagnostic agents.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $122.00.

Several equities analysts have recently issued reports on the company. Morgan Stanley reissued an "overweight" rating and set a $130.00 target price on shares of Monopar Therapeutics in a research note on Monday, August 17th. Cantor Fitzgerald lowered Monopar Therapeutics from an "overweight" rating to a "neutral" rating and raised their price target for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Zacks Research cut shares of Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 13th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Friday, July 17th.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $78.96 on Friday. The stock has a market capitalization of $529.82 million, a PE ratio of -36.39 and a beta of 1.50. Monopar Therapeutics has a 1 year low of $50.07 and a 1 year high of $124.82. The business's 50-day moving average is $104.34 and its 200 day moving average is $83.50.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02. As a group, equities research analysts anticipate that Monopar Therapeutics will post -2.98 earnings per share for the current year.

Insider Activity at Monopar Therapeutics

In related news, CEO Chandler Robinson sold 29,056 shares of the stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares of the company's stock, valued at $8,735,496. This represents a 22.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Starr sold 8,400 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $78.50, for a total value of $659,400.00. Following the transaction, the director owned 5,173 shares in the company, valued at $406,080.50. This trade represents a 61.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,688 shares of company stock worth $4,023,094 over the last ninety days. Corporate insiders own 9.70% of the company's stock.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Siren L.L.C. lifted its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock valued at $14,800,000 after buying an additional 57,820 shares during the period. ADAR1 Capital Management LLC increased its stake in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock worth $14,480,000 after acquiring an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Monopar Therapeutics by 21.2% in the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company's stock worth $4,307,000 after acquiring an additional 13,761 shares in the last quarter. Walleye Capital LLC purchased a new position in Monopar Therapeutics during the 1st quarter valued at about $3,458,000. Finally, Bank of America Corp DE lifted its position in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company's stock valued at $3,271,000 after acquiring an additional 53,336 shares during the period. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company's research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar's portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.